Patents by Inventor Andrew Souers

Andrew Souers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230399340
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: October 12, 2022
    Publication date: December 14, 2023
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Andreas Kling, Frauke Pohlki, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Michael Michaelides
  • Patent number: 11786519
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 17, 2023
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20220259226
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: April 22, 2022
    Publication date: August 18, 2022
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Yujia Dai, Jane Gong, Roberto Risi, Yiyun Yu, Guidong Zhu
  • Publication number: 20210403467
    Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
    Type: Application
    Filed: February 4, 2021
    Publication date: December 30, 2021
    Inventors: Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
  • Publication number: 20210346369
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 1, 2020
    Publication date: November 11, 2021
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20210292339
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: October 23, 2020
    Publication date: September 23, 2021
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU
  • Publication number: 20210228565
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: September 16, 2020
    Publication date: July 29, 2021
    Applicant: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20200345717
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 5, 2020
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20200331907
    Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bc1-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 22, 2020
    Inventors: Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
  • Publication number: 20200255451
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: August 13, 2020
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU, Dominique POTIN, Fabrice Guillier
  • Publication number: 20200253954
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20200239494
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: July 30, 2020
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Michael Michaelides
  • Publication number: 20200222413
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 16, 2020
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • Publication number: 20180369250
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL.
    Type: Application
    Filed: December 12, 2017
    Publication date: December 27, 2018
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • Publication number: 20180354952
    Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 13, 2018
    Inventors: Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
  • Patent number: 10081628
    Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. One embodiment of such compounds is 4-(4-{[2-(4-chloro-2-fluorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 25, 2018
    Assignee: AbbVie Inc.
    Inventors: Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
  • Publication number: 20180221363
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20180140595
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: November 3, 2017
    Publication date: May 24, 2018
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 9877958
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: January 30, 2018
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 9872861
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 23, 2018
    Assignee: AbbVie Inc.
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper